Background/Aims: The hematopoietic system is vulnerable to ionizing radiation and is often severely damaged by radiation. Molecules affecting radioresistance include Toll-like receptor 2. We investigated whether Zymosan-A, a novel TLR2 agonist, can protect the hematopoietic system from radiation-induced damage after total body irradiation. Methods: Mice were exposed to total body radiation after treatment with Zymosan-A or normal saline, and their survival was recorded. Tissue damage was evaluated by hematoxylin-eosin staining. The number of nucleated cells in bone marrow was determined by flow cytometry. Cell viability and apoptosis assay were determined by CCK-8 assay and flow cytometry assay. Enzymelinked immunosorbent assay was used to detect the level of cytokines. Results: Zymosan-A protected mice from radiation-induced death and prevented radiation-induced hematopoietic system damage. Zymosan-A also promoted cell viability and inhibited cell apoptosis caused by radiation, induced radioprotective effects via TLR2, upregulated IL-6, IL-11, IL-12, and TNF-α in vivo. Conclusion: Zymosan-A can provide protection against radiation-induced hematopoietic system damage by targeting the TLR2 signaling pathway. Thus, Zymosan-A can be potentially effective radioprotectant.
Introduction
Most patients with tumor receive radiotherapy [1] [2] [3] . Inevitable radiotherapy at different doses causes injury to normal tissues and affects tumor cells. The bone marrow hematopoietic system is the most sensitive system in the human body [4, 5] . This sensitivity limits the use of radiotherapy in patients with tumor. Thus, novel and effective radioprotective drugs need to be developed [6] [7] [8] [9] .
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry Bone marrow histological examination. Mouse femurs were removed and then fixed in 4% paraformaldehyde at 1, 5, 10, 15, and 30 d postirradiation. The cells were then stained with hematoxylin and eosin (HE).
Enzyme-linked immunosorbent assay (ELISA)
Blood was collected from the mice 24 h post-irradiation and stored at room temperature for 30 min. The blood was then centrifugated at 3000 rpm/min for 10 min. Serum was then collected and stored at -20 °C. The levels of IL-6, IL-11, IL-12, and TNF-α were analyzed by ELISA. All steps were operated as instructed.
Statistical analysis.
Data were expressed as means ± the standard errors of means. Two-tailed Student's t-test was used to analyze the difference between 2 groups. ANOVA was employed to analyze the difference among 3 groups. Kaplan-Meier analysis was applied to estimate the difference of overall survival between 2 groups. The data were analyzed using SPSS ver. 19 (IBM Corp., Armonk, NY, USA). P<0.05 was considered statistically significant.
Results

Zymosan-A exhibited a significant radioprotective effect in vivo
To prove the radioprotective function of Zymosan-A in vivo, C57BL/6 mice were administered with a total of 50 mg/kg Zymosan-A 24 and 2 h before TBI. The results indicated that the survival rates of Zymosan-A group were increased after TBI (Figs. 1A-1D ), and the dose reduction factor (DRF) was 1.25 (Zymosan-A vs. NS) (Fig. 1E ). These data demonstrated that the TLR2 agonist Zymosan-A exerted a significant radioprotective effect in vivo.
Zymosan-A protected the hematopoietic system against radiation-induced damage HE staining was employed to evaluate the radioprotective effect of Zymosan-A on the hematopoietic system. The hematopoietic system damage in the NS group was found to be more severe than that in the Zymosan-A group. The radiation damage on the structure of the bone marrow was alleviated in the Zymosan-A group. The number of nucleated cells was greater in the Zymosan group than in the NS group. Moreover, the bone marrow recovered much faster in the Zymosan-A than in the NS group ( Fig. 2A) . We also found that treatment with Zymosan-A increased the number of PWBCs, BMCs, and spleen coefficients (Figs. 2B-2D) . Combined, these data indicated that Zymosan-A protected the hematopoietic system against radiation-induced damage, potentially inducing death in mice post-radiation. 
Zymosan-A promoted cell viability and inhibited cell apoptosis caused by radiation.
To verify the radioprotective function of Zymosan-A in vitro, we assayed the cell viability and apoptosis of HIEC and AHH-1 cell lines 24 h after radiation (4 or 8 Gy). We found that Zymosan-A inhibited cell apoptosis in AHH-1 (Figs. 3A-3B ) and promoted cell viability in HIEC (8 Gy) (Fig. 3C) .
Zymosan-A induced radioprotective effects via TLR2.
In our previous study, we showed that TLR2/4 played critical roles in radioresistance in vivo [15, 16] . Compared with the WT mice, the TLR2-/-and TLR4-/-mice were more susceptible to radiation-induced deaths (Figs. 4A-4B ). Zymosan-A protected TLR4-/-mice from radiation-induced death, but had no radioprotective effects to the TLR2-/-mice (Figs.  4C-4D ). These findings consistently indicated that Zymosan-A induced radioprotective effects via TLR2 but not via TLR4.
Zymosan-A upregulated IL-6, IL-11, IL-12, and TNF-α in vivo.
We verified that Zymosan-A induced radioprotective effects via TLR2. To further determine the possible mechanism involved, we detected the serum IL-6, IL-11, IL-12, and 
Figure. 6
TNF-α levels in the mice pretreated with Zymosan-A; the serum levels of IL-6, IL-11, IL-12 and TNF-α were upregulated in vivo 24 h post-radiation (Fig. 5) .
Discussion
Many studies indicated that activation of the TLRs signaling pathways can provide protection against radiation-induced damage [14-16, 18, 24, 25] . In our previous studies, we showed that TLR2 and TLR4 played critical roles in radioresistance. TLR2-/-and TLR4-/-mice were more susceptible to irradiation-induced mortality and morbidity [15, 16] .
To the best of our knowledge, this study is the first report to prove that Zymosan-A can protect against radiation-induced damage in vivo and in vitro by targeting TLR2. Zymosan-A, an extract of yeast cell wall, is proven to be a potential agonist of TLR2 [26] [27] [28] . After treatment with Zymosan-A, the survival rates of the mice were increased after TBI. HE staining showed that Zymosan-A protected the hematopoietic system against radiation-induced damage, which may lead to death in mice post-radiation. The number of BMC and PWBCs and the spleen coefficients were also increased after treatment with Zymosan-A. By using cultured human cells, we showed that Zymosan-A promoted cell viability and inhibited cell apoptosis caused by radiation. The findings indicated that Zymosan-A protected the hematopoietic system against radiation-induced damage in vivo and in vitro.
To determine the possible mechanism underlying radioprotection by Zymosan-A, we used TLR2-/-and TLR4-/-mice. The results showed that Zymosan-A protected TLR4-/-mice but not TLR2-/-mice from radiation-induced death. These data consistently indicated that Zymosan-A induced radioprotective effects via TLR2 but not TLR4. Many studies indicated that Zymosan-A can induce NF-κB phosphorylation and nuclear translocation by targeting TLR2 [21, 22, 29] . Zymosan-A can also upregulate cytokines, including TNF-α; the IL-1 family; the IL-6, IL-8, and IL-10 family; IL-11; IL-23; the IL-12 family; IL-15; TGF-β; and G-CSF [30] [31] [32] [33] [34] . In addition, IL-6, IL-11, IL-12, G-CSF, and TNF-α are regarded as radiation protection factors [35] [36] [37] [38] [39] [40] . In the current study, we proved that Zymosan-A upregulated the serum levels of IL-6, IL-11, IL-12, and TNF-α in vivo. Our study proved that Zymosan-A exerts marked radioprotective effects in vivo and in vitro by targeting the TLR2 signaling pathway (Fig. 6) .
In conclusion, our findings showed that Zymosan-A can provide protection against radiation-induced damage by targeting the TLR2 signaling pathway. These data suggested that Zymosan-A can be a potentially effective radioprotectant.
